21 May 2009
Individualization of immunosuppressive therapy
B D KahanAnn Transplant 2009; 14(1): 20-20 :: ID: 880272
Abstract
This "Meet the Professor" discussion session is divided into four segments:
pre-morbid donor features (5 minutes), pre-transplant morbid donor events
(5 minutes), pre-transplant characteristics of potential recipients (10 minutes), and post-transplant recipient events (15 minutes). Each section will include a brief presentation and questions. The pre-morbid donor features include age over 50 years, pharmacogenomics, kidney size, and concomitant diseases. The morbid donor events include the etiology of death, preretrieval pathophysiologic events and intraoperative events. The pretransplant recipient characteristics are gender, age, ethnicity, medical regimen, pharmacogenomics, unrecognized malignancy/infection, HLA mismatch, socioeconomic education level, donor source, and immune responder status. The post-transplant recipient events include cold ischemia time, concomitant drug therapies, complications, chronic allograft disease, rejection episodes and non-compliance. Literature citations will be provided and informal discussion offered after the session.
Keywords: immunosuppressive therapy
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






